[go: up one dir, main page]

MXPA03000316A - Reactivos y metodos para la identificacion de agentes de enlace. - Google Patents

Reactivos y metodos para la identificacion de agentes de enlace.

Info

Publication number
MXPA03000316A
MXPA03000316A MXPA03000316A MXPA03000316A MXPA03000316A MX PA03000316 A MXPA03000316 A MX PA03000316A MX PA03000316 A MXPA03000316 A MX PA03000316A MX PA03000316 A MXPA03000316 A MX PA03000316A MX PA03000316 A MXPA03000316 A MX PA03000316A
Authority
MX
Mexico
Prior art keywords
protein
threonine
polypeptide
peptide
interaction
Prior art date
Application number
MXPA03000316A
Other languages
English (en)
Inventor
Peter Davies
Original Assignee
Molecular Geriatrics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Molecular Geriatrics Corp filed Critical Molecular Geriatrics Corp
Publication of MXPA03000316A publication Critical patent/MXPA03000316A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G01N33/575—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Se describe un metodo para identificar un agente de enlace deseado que interfiere con la interaccion entre una proteina, fragmento de proteina, polipeptido o un peptido y un sustituto de enlace. El metodo comprende la combinacion de la proteina, el fragmento de proteina, el polipeptido o el peptido, el sustituto de enlace y un agente de enlace. La deteccion de una disminucion en la interaccion entre la proteina, el fragmento de proteina, el polipeptido o peptido a partir del sustituto de enlace, detecta que el agente de enlace interfiere con la interaccion. Las proteinas utiles en el metodo incluyen la proteina tau fosforilada en la treonina (231), la Proteina Precursora Amiloide (APP) fosforilada en la treonina (668), y cdc25 fosforilada en la treonina (48). Los compuestos identificados mediante el metodo son utiles en el tratamiento de la enfermedad de Alzheimer y el cancer.
MXPA03000316A 2000-07-11 2001-07-11 Reactivos y metodos para la identificacion de agentes de enlace. MXPA03000316A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21760400P 2000-07-11 2000-07-11
PCT/US2001/021859 WO2002004949A2 (en) 2000-07-11 2001-07-11 Reagents and methods for identification of binding agents

Publications (1)

Publication Number Publication Date
MXPA03000316A true MXPA03000316A (es) 2004-04-05

Family

ID=22811750

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03000316A MXPA03000316A (es) 2000-07-11 2001-07-11 Reactivos y metodos para la identificacion de agentes de enlace.

Country Status (7)

Country Link
US (1) US20050221391A1 (es)
EP (1) EP1301531A2 (es)
JP (1) JP2004503747A (es)
AU (1) AU2001273361A1 (es)
CA (1) CA2415919A1 (es)
MX (1) MXPA03000316A (es)
WO (1) WO2002004949A2 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7799526B2 (en) 2002-11-21 2010-09-21 The University Of North Carolina At Chapel Hill Phosphoprotein detection reagent and methods of making and using the same
JP2006525300A (ja) * 2003-05-02 2006-11-09 スコティッシュ バイオメディカル リミテッド 低分子量ＧＴＰアーゼのＲａｐファミリーに属するタンパク質のグアニンヌクレオチド交換因子の制御
WO2007068105A1 (en) * 2005-12-12 2007-06-21 Robarts Research Institute Method of diagnosing amyotrophic lateral sclerosis
SI2408807T1 (sl) * 2009-03-18 2021-11-30 Ac Immune Sa Postopek za terapevtsko uporabo
UA107571C2 (xx) 2009-04-03 2015-01-26 Фармацевтична композиція
WO2011056561A1 (en) * 2009-10-27 2011-05-12 Beth Israel Deaconess Medical Center Methods and compositions for the generation and use of conformation-specific antibodies
AU2013205313B2 (en) * 2010-10-07 2016-05-19 Ac Immune S.A. Phosphospecific antibodies recognising tau
JP6371526B2 (ja) * 2010-10-07 2018-08-08 エーシー イミューン エス．エー． タウを認識するリン酸化部位特異的抗体
WO2012149334A2 (en) * 2011-04-27 2012-11-01 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for the generation and use of conformation-specific antibodies
BR112014008202B1 (pt) 2011-10-07 2022-01-04 Ac Immune S.A. Anticorpo, polinucleotídeo, composição farmacêutica, usos de um anticorpo, método in vitro, método de detecção da formação de um complexo imunológico, método de detecção post­mortem de multimêros do fosfo-tau, kits de teste, linhagem celular isolada e método de detecção de multimêros de fosfo-tau
MX356800B (es) 2012-04-05 2018-06-13 Ac Immune Sa Anticuerpo tau humanizado.
ES2775192T3 (es) 2012-08-16 2020-07-24 Ipierian Inc Procedimientos de tratamiento de una tauopatía
US8980270B2 (en) 2013-01-18 2015-03-17 Ipierian, Inc. Methods of treating a tauopathy
WO2014150877A2 (en) 2013-03-15 2014-09-25 Ac Immune S.A. Anti-tau antibodies and methods of use
EP3104870A4 (en) 2014-02-14 2017-09-13 Ipierian, Inc. Tau peptides, anti-tau antibodies, and methods of use thereof
CA3079423A1 (en) 2017-10-25 2019-05-02 Janssen Pharmaceuticals, Inc. Compositions of phosphorylated tau peptides and uses thereof
JOP20210211A1 (ar) 2019-02-08 2023-01-30 Janssen Pharmaceuticals Inc طريقة إعطاء دواء آمنة للقاح ببتيد تاو المفسفر
BR112021021213A2 (pt) 2019-04-24 2021-12-21 Ac Immune Sa Administração heteróloga de vacinas de tau

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0544942A1 (en) * 1991-12-06 1993-06-09 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Novel tools for the diagnosis and treatment of Alzheimer disease
WO1994019692A1 (en) * 1993-02-18 1994-09-01 The General Hospital Corporation Alzheimer's disease therapeutics
US20020086009A1 (en) * 1996-03-13 2002-07-04 Koichi Ishiguro Anti-phosphorylated tau protein antibodies and methods for detecting alzheimer`s disease with the use of the same
AU5508798A (en) * 1996-11-19 1998-06-10 Trustees Of The University Of Pennsylvania, The Diagnostic and therapeutic reagents for alzheimer's disease
US6495376B1 (en) * 1999-02-18 2002-12-17 Beth Israel Deaconess Medical Center Methods and compositions for regulating protein-protein interactions

Also Published As

Publication number Publication date
WO2002004949A3 (en) 2002-10-03
EP1301531A2 (en) 2003-04-16
AU2001273361A1 (en) 2002-01-21
US20050221391A1 (en) 2005-10-06
WO2002004949A2 (en) 2002-01-17
CA2415919A1 (en) 2002-01-17
JP2004503747A (ja) 2004-02-05

Similar Documents

Publication Publication Date Title
MXPA03000316A (es) Reactivos y metodos para la identificacion de agentes de enlace.
EA200501891A1 (ru) Гуманизированные антитела, распознающие бета-амилоидный пептид
EA200300637A1 (ru) Гуманизированные антитела, распознающие бета-амилоидный пептид
WO2005018424A3 (en) Antibodies specific for fibrillar amyloid and a procedure to detect fibrillar amyloid deposits
ATE485303T1 (de) Isoformen von gehirn-natriuretischem peptid
AT500379A3 (de) Tau-proteine
EA200401170A1 (ru) Гуманизированные антитела, распознающие бета-амилоидный пептид
BRPI0415230A (pt) anticorpo biespecìfico de substituição de proteìnas funcionais
CY1110923T1 (el) Συζυγη που περιλαμβανουν ενα αντισωμα ειδικο για την ed-β περιοχη της ινονεκτινης και η χρηση τους για τον εντοπισμο και την αντιμετωπιση ογκων
EE200700052A (et) Antikeha he v?i mitme apo-lipoproteiin B fragmendi vastu
WO2003039467A3 (en) Monoclonal antibodies specific for beta-amyloid.
EA200700083A1 (ru) Антитела, направленные против бета-амилоидного пептида, и способы их применения
DE69129302D1 (de) Inhibitoren des tumorwachstums aus geweben, methoden ihrer herstellung und verwendungen
AR046415A1 (es) Mimeticuerpos de nucleo de bisagra epo- mimeticos humanos, composiciones, metodos y usos
BR0315157A (pt) Métodos de tratar doença de alzheimer empregando-se anticorpos direcionados contra peptìdeo beta amilóide e composições deste
DE60032486D1 (de) Prion protein peptide und deren verwendung
ES2170104T3 (es) Inhibidores de la produccion de proteinas de beta-amiloide.
EA200300464A1 (ru) ГУМАНИЗИРОВАННОЕ АНТИТЕЛО ПРОТИВ РЕЦЕПТОРА ЛИМФОТОКСИНА-β (ВАРИАНТЫ), КОМПОЗИЦИЯ, СПОСОБ ЛЕЧЕНИЯ ИЛИ СНИЖЕНИЯ РИСКА РАЗВИТИЯ, ТЯЖЕСТИ ИЛИ ПОСЛЕДСТВИЙ НЕОПЛАЗИИ У ЧЕЛОВЕКА, ВЫДЕЛЕННАЯ НУКЛЕИНОВАЯ КИСЛОТА (ВАРИАНТЫ), КЛЕТКА КЛЕТОЧНОЙ ЛИНИИ
MX2007013626A (es) Anticuerpos dirigidos contra el peptido beta amiloide y procedimientos que usan los mismos.
DK1521774T3 (da) Trunkerede Tau-proteiner
MX9303082A (es) Proteasa y componentes relacionados con el dna.
EP1541686A4 (en) ANTIBODY CONSTRUCTION USING AN MRL / LPR MOUSE
ATE368688T1 (de) Peptide, deren herstellung und verwendung zur bindung von immunglobulinen
BRPI0413495A (pt) reagentes de peptìdeos especìficos para prìons e seus usos
ES2085993T3 (es) Proteina asociada a la pancreatitis aguda, medios para el diagnostico de la pancreatitis aguda.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal